CJC-1295 No DAC 10 mg Research Peptide (Modified GRF 1-29)

What is CJC-1295 No DAC?

CJC-1295 No DAC is a synthetic 29-amino-acid analog of growth hormone-releasing hormone (GHRH), also sold as modified GRF(1-29). It is the human GRF(1-29) sequence with four substitutions: D-alanine at position 2, glutamine at 8, alanine at 15 and leucine at 27. This product is a 10 mg PEPTYVA vial for laboratory research use only, not for human or veterinary use.

The name causes confusion. In the 2005 paper that introduced CJC-1295, the name covers this substituted sequence plus an extra C-terminal lysine carrying a maleimidopropionamide group that binds albumin. The free 29-residue peptide without that lysine is what suppliers label No DAC, and anti-doping papers list it as an analyte separate from CJC-1295 with drug affinity complex (DAC).

How is modified GRF(1-29) studied in research?

It is studied as a GHRH receptor agonist designed to resist breakdown. Earlier work on stabilized GRF analogs explains the logic of each substituted position: native GRF is cut by dipeptidylpeptidase IV between residues 2 and 3, asparagine at position 8 rearranges in water, methionine at position 27 oxidizes, and alanine in place of glycine at position 15 had been reported to increase receptor binding affinity.

Those design papers tested related analogs, not this exact sequence, so they explain the design rather than measure this peptide. The 2005 rat and cell work that produced CJC-1295 used this same substituted core, but its measurements concern the albumin-reactive form.

What does the current evidence show?

Evidence for this exact peptide is thin. A PubMed search did not identify published controlled studies of modified GRF(1-29) in people. The human pharmacology data often quoted for CJC-1295 come from the DAC version, whose albumin binding changes how long it circulates, so those figures cannot be applied to this peptide.

Most publications that name the non-DAC peptide are analytical. Anti-doping laboratories have described methods to detect it in urine, and a Norwegian laboratory identified a 29-residue peptide matching it in a preparation submitted by police and customs and marketed as CJC-1295. That work documents its chemistry and circulation, not its effects, which have not been established in people.

How does CJC-1295 No DAC differ from CJC-1295 with DAC?

The difference is one added residue with a large consequence. The DAC version ends with a lysine bearing a maleimidopropionyl group, which lets it attach covalently to the free thiol on cysteine 34 of serum albumin. This No DAC peptide has no such group. It stays a free 29-residue peptide like sermorelin and differs from sermorelin only at the four substituted positions.

The vials also differ: this listing holds 10 mg, while the DAC listing holds 5 mg. Their molecular weights are 3367.9 g/mol here and 3647.2 g/mol for the DAC compound, according to PubChem.

What is the regulatory status of CJC-1295 No DAC?

We found no approved medicine containing this peptide; Drugs@FDA lists none. The FDA page on compounding substances that may present significant safety risks names CJC-1295 among nominations later withdrawn, without stating which form. In Mexico, this vial is sold only as laboratory research material and is not a registered medicine.

Documentation

Each CJC-1295 No DAC vial carries a PEPTYVA lot number. The lot's Certificate of Analysis (COA) reports identity and purity, which matters for a peptide often confused with its DAC relative. Request the COA through our contact page; see Quality & Documentation for how to read it.

Storage and handling

Hold the unopened vial in its sealed original box, out of light and away from moisture and heat, at the temperature stated on the PEPTYVA label. Confirm the seal and the lot number on arrival.